Book:Common viral infections

Respiratory Syncytial Virus Infections - Pipeline Review, H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 19, 2020
Health, Infectious diseases, Health, Medical specialties, Clinical medicine, Human orthopneumovirus, Paramyxoviridae, RSV, Virus, Respiratory syncytial virus vaccine, Book:Common viral infections

The "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of the Respiratory Syncytial Virus Infections (Infectious Disease) pipeline landscape.
  • The Respiratory Syncytial Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses

Retrieved on: 
Monday, May 4, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Mononegavirales, Viruses, Human metapneumovirus, Microbiology, Human orthopneumovirus, Vaccine, Orthopneumovirus, Pneumoviridae, Book:Common viral infections

Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgenes (Paris:TNG) proprietary DuckCelt-T17 cell line.

Key Points: 
  • Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgenes (Paris:TNG) proprietary DuckCelt-T17 cell line.
  • It will allow us to continue developing our vaccines against respiratory viruses namely a monovalent vaccine against human Metapneumovirus and a bivalent one against Respiratory Syncytial Virus and human Metapneumovirus.
  • We are glad to valorize an asset such as our DuckCelt-T17 cell line with Vaxxels high potential projects.
  • Vaxxel develops live-attenuated vaccines against Metapneumovirus and against the Respiratory Syncytial Virus based on the Metavac vaccine platform.

West Nile Virus Infections - World Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 9, 2019
Infectious diseases, Pharmaceutical, Health, Animal diseases, Medicine, Veterinary medicine, Encephalitis, Flaviviruses, Tropical diseases, West Nile, Virus, Infection, Book:Common viral infections

The "West Nile Virus Infections - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "West Nile Virus Infections - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The West Nile Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for West Nile Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding West Nile Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

SpeeDx Develops Multiplex Test for Respiratory Viruses

Retrieved on: 
Tuesday, February 12, 2019
Health, Biotechnology, Genetics, Infectious diseases, Research, Medical Supplies, Science, Viruses, Mononegavirales, Paramyxoviridae, Human metapneumovirus, Orthopneumovirus, Human orthopneumovirus, Influenza, Human parainfluenza viruses, Rhinovirus, Viral pneumonia, Book:Common viral infections

The test utilises SpeeDx market-leading PlexPCR multiplex technology, designed for detection of 14 targets representing 10 viral respiratory-illness causing pathogens.

Key Points: 
  • The test utilises SpeeDx market-leading PlexPCR multiplex technology, designed for detection of 14 targets representing 10 viral respiratory-illness causing pathogens.
  • View the full release here: https://www.businesswire.com/news/home/20190212006006/en/
    SpeeDx PlexPCR RespiVirus offers excellent sensitivity and improved productivity for fast and reproducible respiratory virus testing.
  • (Graphic: Business Wire)
    We are excited to expand our infectious disease portfolio into the respiratory market, said Colin Denver, SpeeDx CEO.
  • The SpeeDx PlexPCR RespiVirus test detects major respiratory pathogens including Influenza A, Influenza B, Rhinoviruses (A & B), Respiratory Syncytial Viruses (A & B), Human metapneumovirus, Adenoviruses, and Human parainfluenza viruses 1, 2, 3 and 4.